Phase II Study of Dasatinib in Patients With Advanced Non–Small-Cell Lung Cancer

摘要: Purpose Src family kinases (SFKs) promote cancer progression and are commonly expressed in non–small-cell lung (NSCLC), but the clinical effects of SFK inhibition NSCLC unknown. We conducted a phase II trial inhibitor dasatinib for advanced NSCLC. tested hypotheses that activation epidermal growth factor receptor (EGFR) or modulation serum cytokines may predict response to dasatinib. Patients Methods received as first-line therapy. Response was measured by tumor size on computed tomography scans metabolic activity positron emission scans. Tissue samples taken before patients were EGFR Kras mutation phosphorylated expression. Results Thirty-four enrolled. The overall disease control rate (partial responses plus stable disease) 43%. One patient had partial Eleven (32%) SF...